What is she best known for?
The fields of study she is best known for:
- Cancer
- Internal medicine
- Gene
Her main research concerns Crizotinib, Anaplastic lymphoma kinase, Cancer research, Lung cancer and Internal medicine.
Her study in ALK inhibitor, Lorlatinib, Ceritinib and ALK Gene Rearrangement is done as part of Crizotinib.
Her Ceritinib research includes elements of Tolerability and Alectinib.
Her research investigates the link between Anaplastic lymphoma kinase and topics such as ROS1 that cross with problems in Kinase and Mutation.
Her studies deal with areas such as Cancer, Tyrosine kinase, Molecular biology, Entrectinib and Drug resistance as well as Cancer research.
She has included themes like Gastroenterology, Surgery and Oncology in her Internal medicine study.
Her most cited work include:
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer (3607 citations)
- Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer (2444 citations)
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors (2242 citations)
What are the main themes of her work throughout her whole career to date?
Internal medicine, Oncology, Lung cancer, Crizotinib and Cancer research are her primary areas of study.
Her research in the fields of non-small cell lung cancer, Chemotherapy and Adverse effect overlaps with other disciplines such as In patient.
The concepts of her Oncology study are interwoven with issues in Clinical endpoint, Clinical trial and Phases of clinical research.
Her Lung cancer research integrates issues from Cancer, Targeted therapy, Carcinoma and Lung.
Her Crizotinib study frequently links to related topics such as Anaplastic lymphoma kinase.
Her research in Cancer research intersects with topics in Mutation, Tyrosine kinase, Tyrosine-kinase inhibitor, ROS1 and Kinase.
She most often published in these fields:
- Internal medicine (58.74%)
- Oncology (51.12%)
- Lung cancer (40.58%)
What were the highlights of her more recent work (between 2019-2021)?
- Internal medicine (58.74%)
- Lung cancer (40.58%)
- Oncology (51.12%)
In recent papers she was focusing on the following fields of study:
Her primary areas of investigation include Internal medicine, Lung cancer, Oncology, Crizotinib and Cancer research.
Her study focuses on the intersection of Lung cancer and fields such as Clinical trial with connections in the field of Progression-free survival, Cancer, Quality of life and Insomnia.
The various areas that Alice T. Shaw examines in her Oncology study include Immunohistochemistry, Clinical endpoint, Phases of clinical research and Hazard ratio.
Her primary area of study in Crizotinib is in the field of Alectinib.
Alice T. Shaw combines subjects such as Targeted therapy, Carcinoma, Lung and Proto-Oncogene Proteins p21 with her study of Cancer research.
As a member of one scientific family, she mostly works in the field of Chemotherapy, focusing on Ceritinib and, on occasion, Discontinuation.
Between 2019 and 2021, her most popular works were:
- Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials (196 citations)
- Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. (71 citations)
- Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. (32 citations)
In her most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
Her main research concerns Internal medicine, Oncology, Lung cancer, Crizotinib and Adverse effect.
Alice T. Shaw studies Tyrosine-kinase inhibitor which is a part of Internal medicine.
Her study in Oncology is interdisciplinary in nature, drawing from both KRAS, Clinical trial and Hazard ratio.
Her Lung cancer study combines topics in areas such as STK11, Blockade, Chemotherapy and Immunotherapy.
Her Crizotinib study focuses mostly on Alectinib and Lorlatinib.
In most of her Lorlatinib studies, her work intersects topics such as Cancer research.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
